抑制硬化蛋白与DKK1可保存并增加牙槽骨丢失大鼠的牙槽骨量与结构
研究在大鼠牙槽骨丢失模型中评估抑制硬化蛋白(SAB)与DKK1(DAB)的效果。卵巢切除大鼠下颌骨丢失可被单用SAB及SAB+DAB逆转;上颌磨牙拔除模型中SAB增加萎缩牙槽嵴体积与高度,联用DAB效果增强,并逆转对颌骨低咬合所致骨丢失。
要点
- SAB单用及联合DAB可逆转雌激素缺乏大鼠的下颌骨丢失。
- 磨牙拔除模型中SAB增加牙槽嵴体积与高度,联用DAB效果增强。
- SAB/SAB+DAB增加牙槽骨时伴颅后骨骼骨量增加,需关注全身效应。
核心结论
- 抑制硬化蛋白,联合或不联合DKK1共抑制,均可增加牙槽骨丢失大鼠的牙槽骨量与改善骨结构。
- 此类非侵入性方法或可用于牙槽骨的保守性增量。
研究设计与样本
- 大鼠在体研究:雌激素缺乏卵巢切除模型与上颌磨牙拔除模型,给予全身性SAB单用或SAB+DAB。
- 另采用硬化蛋白缺陷小鼠比较下颌骨生物力学与野生型对照。
主要发现
- 卵巢切除大鼠出现显著下颌骨丢失,单用SAB及SAB+DAB可逆转。
- 有牙与无牙大鼠上颌骨细胞表达Sost与Dkk1 mRNA,磨牙拔除似急性增加DKK1表达。
- 慢性上颌磨牙拔除模型中,SAB增加萎缩牙槽嵴体积与高度,联用DAB增强该效应。
- SAB与SAB+DAB完全逆转对颌因低咬合发生的骨丢失。
- 两项治疗研究中牙槽骨增量均伴颅后骨骼骨量增加;硬化蛋白缺陷小鼠下颌骨更强更致密。
临床怎么用
- 提示抑制硬化蛋白/DKK1可能作为牙槽骨保守增量的非侵入性策略,但尚处动物研究阶段。
局限性
- 证据来自大鼠与小鼠实验,结论不能直接外推至人群临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alveolar bone is a mechanosensitive tissue that provides structural support for teeth. Alveolar bone loss is common with aging, menopause, tooth loss, and periodontitis and can lead to additional tooth loss, reduced denture fixation, and challenges in placing dental implants. The current studies suggest that sclerostin and DKK1, which are established osteocyte-derived inhibitors of bone formation, contribute to alveolar bone loss associated with estrogen ablation and edentulism in rats. Estrogen-deficient ovariectomized rats showed significant mandibular bone loss that was reversed by systemic administration of sclerostin antibody (SAB) alone and in combination with DKK1 antibody (DAB). Osteocytes in the dentate and edentulous rat maxilla expressed Sost (sclerostin) and Dkk1 (DKK1) mRNA, and molar extraction appeared to acutely increase DKK1 expression. In a chronic rat maxillary molar extraction model, systemic SAB administration augmented the volume and height of atrophic alveolar ridges, effects that were enhanced by coadministering DAB. SAB and SAB+DAB also fully reversed bone loss that developed in the opposing mandible as a result of hypo-occlusion. In both treatment studies, alveolar bone augmentation with SAB or SAB+DAB was accompanied by increased bone mass in the postcranial skeleton. Jaw bone biomechanics showed that intact sclerostin-deficient mice exhibited stronger and denser mandibles as compared with wild-type controls. These studies show that sclerostin inhibition, with and without DKK1 coinhibition, augmented alveolar bone volume and architecture in rats with alveolar bone loss. These noninvasive approaches may have utility for the conservative augmentation of alveolar bone.
引用
- Liu M, Kurimoto P, Zhang J, et al. Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss. J Dent Res. 2018. PMID: 29617179. doi:10.1177/0022034518766874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。